|Healthcare Review: Discovery Laboratories, Cyclacel Pharmaceuticals, Sucampo Pharmaceuticals, Geron Corporation, Health Net Are Notable Movers|
|By Staff and Wire Reports|
|Tuesday, 04 December 2012 15:04|
Obama rejected a Republican proposal to resolve a looming fiscal crisis as "still out of balance" and said any deal must include a rise in income tax rates on the wealthiest Americans.
Following are the notable movers at mid day on Tuesday:-
Discovery Laboratories, Inc.(NASDAQ:DSCO) moves up 5% today after releasing data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with Surfaxin may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia.
Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC) pops up 9% today after announcing earlier that it will present analysis of Phase III testing of its leukemia drug candidates Sapacitabine and Decitabine. The testing was administered in alternating cycles in elderly patients with newly diagnosed acute myeloid leukemia at American Society of Hemoatology convention in Atlanta this weekend.
Shares of Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) extend yesterday's slide on the back of the FDA's reveiw extension of the company's Amitiza drug to treat opioid-induced constipation in patients with chronic, noncancer pain. Shares of the company are down 4%.
Geron Corporation(NASDAQ:GERN) gets slammed by 26% after the drug developer announced late yesterday that it has stopped developing its treatment for brain cancers and will cut its workforce by 40% and replace its CFO. Along with the fundamental knock, the stock also has broken through key technical support and is setting a new 10-year low.
Health Net, Inc.(NYSE:HNT) takes an early lead out of the gate this morning on an upgrade to Outperform at Wells Fargo. The firm says the health insurer has dealt with most of the challenges it has faced in 2012 and has a number of positive catalysts to propel it higher over the near term, including growth opportunities in California, along with its recently signed agreement with the DHCS.